The treatment of systemic hypertension (HTN) in patients with Aortic stenosis (AS) requires a careful balance of lowering the systemic blood pressure without compromising vital organ perfusion and worsening of the symptoms of AS. Treatment of systemic HTN is beneficial because the combination of HTN and AS provides additional overload to the left ventricle. This leads to secondary Left ventricular hypertrophy (LVH), which has been shown to increase cardiovascular risks and mortality and thus early presentation of symptoms of AS. Additionally, presence of HTN may affect the accurate assessment of AS. Different treatment options are available, however no specific treatment guidelines have been established for patients with concomitant AS and HTN. Improved control of HTN is the key to prevent symptom progression and inadvertent early surgery. Angiotensin converting enzyme inhibitors (ACEi) and Angiotensin receptor blockers (ARB) appear to be beneficial. Reassessment of the aortic valve by echocardiography is recommended after HTN is well controlled before deciding on aortic valve replacement (AVR).
Keywords: Aortic stenosis, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, cardiovascular risks, hypertension, pharmacological therapy.
Preoperative Levosimendan. A New Way for Organoprotection
Current Pharmaceutical Design Simultaneous Monitoring of Febuxostat and Uric Acid in Human Serum Samples Using the Direct Square-Wave Voltammetric Method
Current Analytical Chemistry The Relevance of Long-Term Adherence to Non-Pharmacological and Pharmacological Treatment of Hypertension
Current Hypertension Reviews Quantification of Shear Stress and Geometric Risk Factors in Carotid Atherosclerosis: Review and Clinical Evidence
Recent Patents on Medical Imaging (Discontinued) Arterial Stiffness As A Therapeutic Target For Isolated Systolic Hypertension: Focus on Vascular Calcification and Fibrosis
Current Hypertension Reviews The Physiology, Pathophysiology and Therapeutic Potential of Gap Junctions in Smooth Muscle
Current Drug Targets Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology Case Report: Severe Hematological, Muscle and Liver Toxicity Caused by Drugs and Artichoke Infusion Interaction in an Elderly Polymedicated Patient
Current Drug Safety TRP Channels as Therapeutic Targets in Kidney Disease and Hypertension
Current Topics in Medicinal Chemistry Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Circulating and Vascular Bioactive Factors During Hypertension in Pregnancy
Current Bioactive Compounds Anti-oxidative and Anti-microbial Activities of Purified MPN-1-1 from Persicaria nepalensis (Meisn.) Miyabe
Current Pharmaceutical Biotechnology Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Sildenafil Plasma Concentrations in Two HIV Patients with Pulmonary Hypertension Treated with Ritonavir-Boosted Protease Inhibitors
Current HIV Research Role of Renin-Angiotensin System in Vascular Endothelial Dysfunction of Pregnancy-Induced Hypertension
Current Hypertension Reviews Blockade of the Renin-Angiotensin-Aldosterone System: Effects on Hypertensive Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Is Hyperhomocyst(e)inemia A Humoral Predictor of Coronary Heart Disease?
Current Pharmaceutical Design Methylglyoxal and Advanced Glycation Endproducts: New Therapeutic Horizons?
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Device-based Therapies for Resistant Hypertension
Current Pharmaceutical Design Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds